nivolumab,etigilimab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['nivo', 'etigilimab', 'biomarker', 'nivolumab', 'marker ', 'mereo ', '$mreo']
$mreo mereo biopharma reports clinical update and interim biomarker analysis presented at esmo 2022 from activate phase 1b/2 open label study of etigilimab (anti-tigit antibody mph-313) plus nivolumab (anti-pd-1 anti stock news alerts in bio
Over 500 members. DM us for our premium stock alerts.